MAR 23, 2021 9:00 AM PDT

Targeted degradation of the enhancer lysine acetyltransferases CBP and p300

Sponsored by: Bio-Techne
  • Assistant Professor, Harvard Medical School, Boston MA Director, Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center, Boston MA Associate Member, Broad Institute
      Dr. Christopher Ott is a chemical biologist at the Center for Cancer Research at Massachusetts General Hospital (MGH) and Harvard Medical School. The principal focus of his research is to determine mechanisms of malfunctioning gene regulation in cancer, and to develop therapeutic strategies to modulate gene regulatory factors in tumors. His team is developing early-stage chemical probes and prototype drugs directed at modulating critical gene regulatory factors including the first chemical degraders of the enhancer acetyltransferases CBP and p300.
    • Field Applications Manager - Bio-Techne
        Dr. Tim Geiger is a molecular and cellular biologist who has enjoyed a varied career from his postdoctoral work developing in vitro transcriptional recruitment models, to overseeing research teams in diagnostics and pharmaceutical analytical development, to business development in high-throughput immune sequencing. He also guest lectures at UC San Diego on omics and translational medicine. He was an early adopter of the Simple Western technology before joining Bio-techne, where as a Field Applications Manager, he continues to focus on the Simple Western product line.

      Date:  March 23, 2021
      Time: 9:00am (PST),  12:00pm (EST)
      The chromatin regulators CBP and p300 maintain gene expression programs through lysine acetylation of chromatin and transcriptional regulators and by scaffolding functions mediated by several protein-protein interaction domains. We have developed a chemical degrader of p300/CBP, dCBP-1, using in silico modeling and cellular activity assays including capillary-based immunodetection assays (ProteinSimple, WES). We have found that dCBP-1 is exceptionally potent at killing multiple myeloma cells and can abolish the enhancer that drive MYC oncogene expression. As an efficient degrader of this unique class of chromatin regulators, dCBP-1 will be a useful tool for understanding p300/CBP activity at enhancers in both normal and diseased cells.
      Webinars will be available for unlimited on-demand viewing after live event.

      Show Resources
      Show Resources
      • See more
      Connect with us